DynaGen Receives FDA Approval for Methylphenidate Extended Release 20 mg Tablets; Generic Version of Ritalin Extended Release With Estimated Market of $100 Million.

Business Editors/Health & Medical Writers

SOUTH PLAINFIELD, N.J.--(BW HealthWire)--May 10, 2001

DYNAGEN, INC. (OTCBB:DYGN) (BSE:DYGN) today announced its wholly-owned subsidiary, Able Laboratories, Inc. has received Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Methylphenidate Extended Release 20 mg tablets. The approval followed the FDA's Division of Bioequivalence's determination that Able's Methylphenidate Hydrochloride Extended Release Tablets USP, 20 mg, are bioequivalent and, therefore, therapeutically equivalent to the Ritalin-SR(R) 20 mg Tablets of Novartis Pharmaceutical Corporation. IMS Data estimates the generic market for DynaGen's newly approved drug to be $100 million.

"Receiving approval on a sustained release formulation is a big achievement for us," stated C. Robert Cusick, Chairman and Chief Executive Officer of DynaGen, Inc. "This is the third ANDA approval we have received in the past six months. Our investments in our manufacturing facilities and Research and Development are coming to fruition. We now have twelve ANDA filings pending with the FDA. We anticipate receiving several of these approvals over the next three months and the rest before year-end."

DynaGen filed its ANDA for Methylphenidate Extended Release 20 mg tablets in November 2000. Manufacturing of the product will begin immediately at Able Laboratories and the Company anticipates shipment of the product to commence shortly.

DynaGen, Inc. is a rapidly growing developer and manufacturer of generic pharmaceuticals. The focus of the Company is to develop products that offer attractive market opportunities within selected niche markets of the generic drug industry.

In addition to the eight products it is currently selling, the Company has twelve products at various stages of FDA approval.

The Company has recently completed its transition from a manufacturing and distribution company into a sole development and manufacturing entity. As part of the Company's commitment to its new strategic focus, the Company will change its name from DynaGen, Inc. to Able Laboratories, Inc. shortly. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release (as well as information included in oral statements or other written statements made or to be made by DynaGen, Inc.) contain statements that are forward-looking, such statements relate to anticipated future revenues of the companies and success of current product offerings. There is no assurance that the company will receive FDA approvals for its new products or achieve the sales levels that will make the operation profitable. Such forward-looking information involves significant risks and uncertainties that could significantly affect anticipated results in the future and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of DynaGen, Inc. For a description of additional risks, and uncertainties, please refer to DynaGen, Inc., filings with the Securities and Exchange Commission, including Forms 10-KSB and 10-QSB.

Ritalin is a registered trademark of Novartis.